Literature DB >> 30223711

Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches.

Khashayar Dashtipour1, Ali Tafreshi1,2, Jessica Lee1, Brianna Crawley3.   

Abstract

The prevalence of speech disorders among individuals with Parkinson's disease (PD) has been reported to be as high as 89%. Speech impairment in PD results from a combination of motor and nonmotor deficits. The production of speech depends upon the coordination of various motor activities: respiration, phonation, articulation, resonance and prosody. A speech disorder is defined as impairment in any of its inter-related components. Despite the high prevalence of speech disorders in PD, only 3-4% receive speech treatment. Treatment modalities include pharmacological intervention, speech therapy, surgery, deep brain stimulation and vocal fold augmentation. Although management of Parkinsonian dysarthria is clinically challenging, speech treatment in PD should be part of a multidisciplinary approach to patient care in this disease.

Entities:  

Keywords:  Parkinson's disease; dysarthria; hypophonia; levodopa; speech; therapy; vocal fold augmentation; voice

Mesh:

Year:  2018        PMID: 30223711     DOI: 10.2217/nmt-2018-0021

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  11 in total

Review 1.  Voice for Health: The Use of Vocal Biomarkers from Research to Clinical Practice.

Authors:  Guy Fagherazzi; Aurélie Fischer; Muhannad Ismael; Vladimir Despotovic
Journal:  Digit Biomark       Date:  2021-04-16

2.  Brain functional specialization and cooperation in Parkinson's disease.

Authors:  Jinmei Sun; Xiaoran Gao; Qiang Hua; Rongrong Du; Pingping Liu; Tingting Liu; Jinying Yang; Bensheng Qiu; Gong-Jun Ji; Panpan Hu; Kai Wang
Journal:  Brain Imaging Behav       Date:  2021-08-24       Impact factor: 3.978

3.  Characterization of Mild and Moderate Dysarthria in Parkinson's Disease: Behavioral Measures and Neural Correlates.

Authors:  Hanna Steurer; Ellika Schalling; Erika Franzén; Franziska Albrecht
Journal:  Front Aging Neurosci       Date:  2022-05-16       Impact factor: 5.702

4.  Impact of the Severities of Glaucoma on the Incidence of Subsequent Dementia: A Population-Based Cohort Study.

Authors:  Fu-Hsuan Kuo; Jui-Fu Chung; Min-Yen Hsu; Chia-Yi Lee; Jing-Yang Huang; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2020-04-02       Impact factor: 3.390

5.  A mobile-assisted voice condition analysis system for Parkinson's disease: assessment of usability conditions.

Authors:  Javier Carrón; Yolanda Campos-Roca; Mario Madruga; Carlos J Pérez
Journal:  Biomed Eng Online       Date:  2021-11-21       Impact factor: 2.819

6.  Evaluating a Speech-Specific and a Computerized Step-Training-Specific Rhythmic Intervention in Parkinson's Disease: A Cross-Over, Multi-Arms Parallel Study.

Authors:  Anne Dorothée Rösch; Ethan Taub; Ute Gschwandtner; Peter Fuhr
Journal:  Front Rehabil Sci       Date:  2022-01-14

Review 7.  Frameworks for Parkinson's Disease Rehabilitation Addressing When, What, and How.

Authors:  Miriam R Rafferty; Ella Nettnin; Jennifer G Goldman; Jillian MacDonald
Journal:  Curr Neurol Neurosci Rep       Date:  2021-02-22       Impact factor: 5.081

8.  Self-perceptions of speech, voice, and swallowing in motor phenotypes of Parkinson's disease.

Authors:  Matthew Dumican; Christopher Watts
Journal:  Clin Park Relat Disord       Date:  2020-10-02

9.  Behavioural and neuroplastic effects of a double-blind randomised controlled balance exercise trial in people with Parkinson's disease.

Authors:  Malin Freidle; Hanna Johansson; Urban Ekman; Alexander V Lebedev; Ellika Schalling; William H Thompson; Per Svenningsson; Martin Lövdén; Alonso Abney; Franziska Albrecht; Hanna Steurer; Breiffni Leavy; Staffan Holmin; Maria Hagströmer; Erika Franzén
Journal:  NPJ Parkinsons Dis       Date:  2022-01-21

Review 10.  Oral Health Disorders in Parkinson's Disease: More than Meets the Eye.

Authors:  Manon Auffret; Vincent Meuric; Emile Boyer; Martine Bonnaure-Mallet; Marc Vérin
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.